Who Owns Context Therapeutics Stock?
NASDAQ: CNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 68.81%
- Held by insiders
- 1.57%
- Institutional holders
- 97
- Institutions 68.8%
- Insiders 1.6%
- Public and other 29.6%
Who owns Context Therapeutics stock?
Institutional investors own about 68.8% of Context Therapeutics's shares, spread across 97 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 1.57% of CNTX.
The largest institutional holders are Deep Track Capital, Lp (8.08%), Nextech Invest, Ltd. (8.08%) and Soleus Capital Management, L.P. (7.69%). Together, the top 10 institutions control 53.3% of shares outstanding. In their latest filings, 2 of the top 10 institutions increased their CNTX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CNTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Deep Track Capital, Lp | 7.42M | 8.08% | 0.0% |
| Nextech Invest, Ltd. | 7.42M | 8.08% | 0.0% |
| Soleus Capital Management, L.P. | 7.06M | 7.69% | +1.4% |
| Blackrock Inc. | 6.17M | 6.71% | +628.6% |
| Avidity Partners Management, LP | 5.00M | 5.44% | 0.0% |
| Franklin Resources, Inc. | 3.80M | 4.14% | 0.0% |
| Vanguard Capital Management LLC | 3.43M | 3.74% | 0.0% |
| Octagon Capital Advisors LP | 3.05M | 3.32% | -41.9% |
| Blue Owl Capital Holdings LP | 2.93M | 3.19% | -42.4% |
| TCG Crossover Management, LLC | 2.68M | 2.92% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CNTX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.82M | 3.06% |
| iShares Trust-iShares Russell 2000 ETF | 2.29M | 2.50% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 1.40M | 1.52% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.01M | 1.10% |
| iShares Trust-iShares Russell 2000 Growth ETF | 881.59K | 0.96% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 521.00K | 0.57% |
| iShares Trust-iShares Micro-Cap ETF | 311.07K | 0.34% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 249.43K | 0.27% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 227.85K | 0.25% |
| Quantitative Master Series LLC-Master Small Cap Index Series | 203.38K | 0.22% |
Frequently asked questions
Who is the largest shareholder of Context Therapeutics?
Deep Track Capital, Lp is the largest institutional shareholder of CNTX, owning 8.08% of shares outstanding (7.42M shares) as of its latest 13F filing.
What percentage of Context Therapeutics is owned by institutions?
Institutions own about 68.8% of CNTX shares and 69.9% of the public float.
How much of Context Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.57% of CNTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.